SYT11 Human

Synaptotagmin XI (SYT11) is a member of the synaptotagmin family, which consists of membrane-trafficking proteins characterized by an N-terminal transmembrane region, a variable linker, and two C-terminal C2 domains (C2A and C2B) . Synaptotagmins are known for their role in calcium-dependent regulation of membrane trafficking, particularly in synaptic transmission .

Synaptotagmin XI, like other synaptotagmins, is involved in the regulation of neurotransmitter release. It functions as a calcium sensor, binding to calcium ions and facilitating the fusion of synaptic vesicles with the presynaptic membrane . This process is crucial for the release of neurotransmitters into the synaptic cleft, enabling communication between neurons.

SYT11 is predominantly expressed in brain tissue, where it plays a pivotal role in neuronal vesicular trafficking and exocytosis . It is distributed throughout the neuronal cell body, axons, and dendrites, mediating vesicular trafficking and ensuring efficient neurotransmitter release .

Recent studies have highlighted the clinical significance of SYT11 in various cancer types. Abnormal expression of SYT11 has been observed in different tumor types, and its expression levels have been correlated with patient prognosis . Additionally, SYT11 has been implicated in immune infiltration and various molecular pathways, including clathrin-mediated endocytosis and Rho GTPase signaling .

Research on SYT11 has revealed its potential as a therapeutic target. Genome-associated studies and experimental models have shown that SYT11 dysfunction is associated with neurological disorders such as Parkinson’s disease and schizophrenia . Understanding the molecular mechanisms underlying SYT11’s role in these diseases could pave the way for the development of novel therapeutic strategies.